Dynavax Technologies Corporation
NASDAQ:DVAX
Overview | Financials
Company Name | Dynavax Technologies Corporation |
Symbol | DVAX |
Currency | USD |
Price | 13 |
Market Cap | 1,708,915,000 |
Dividend Yield | 0% |
52-week-range | 9.74 - 13.89 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Ryan Spencer |
Website | https://www.dynavax.com |
An error occurred while fetching data.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD